AvantGen Technology Platform Overview

AvantGen is a San Diego-based biotechnology company with Therapeutic and Diagnostics divisions. The Therapeutic Division is dedicated to novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization for therapeutic development.

AvantGen has a proprietary and robust Yeast Display System, large natural human antibody database, fully human antibody (Germliner™) libraries and rapid screening technologies. Additionally, AvantGen has developed a novel platform to generate rabbit monoclonal antibodies and VHH nanobodies with remarkably high affinity and specificity by combining the Yeast Display System and the robust immune responses in rabbits and alpaca.

The power of AvantGen’s technology platform has been well recognized by the National Institutes of Health (NIH). The company has received more than twenty (20) NIH SBIR grants and contract awards to develop novel antibodies against multiple targets for therapeutic, diagnostic and research reagents.

To date, AvantGen has successfully fulfilled 100s of projects for NIH, universities, pharmaceutical and biotechnology companies, facilitating and accelerating their antibody-based therapeutic development through services, partnership collaborations, and technology licensing. This technology overview will reveal in-depth more details.